EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Evidence based management of acute COVID-19

H. Sathischandra

Asian Journal of Internal Medicine · 2022

DOI: 10.4038/ajim.v1i1.32 ↗
AbstractBibliografische Angaben

Abstract

SARS-CoV-2, the causative agent of COVID-19, was sequenced in early January 2020 and the WHO declared a pandemic in early March 2020.The original virus which caused the first outbreak in Wuhan has mutated significantly, with the delta variant giving rise to a major wave globally with much morbidity and mortality. By the last week of December 2021, nearly 280 million cases were reported with well over 5 million deaths. With the emergence of the new omicron variant which is said to be more transmissible, there is a risk of another major wave with the potential for health facilities around the world being overwhelmed.In such a background, health systems must be better prepared to face the challenge, and that should include refining treatment protocols. Preventing hospitalizations with early use of oral antiviral drugs and optimising treatment of severe COVID-19 are equally important. This review aims to outline a management plan based on the stage and severity of the disease by examining the current clinical evidence that has emerged through a multitude of trials. There is general consensus regarding the use of steroids, immunosuppressive therapy and anticoagulation in COVID-19 although there are slight differences in the respective national guidelines.New research is being carried out with oral antiviral drugs for use in early disease and some of the early results are promising. They could play a decisive role in mitigating the effects of the pandemic in addition to vaccination. As many clinical trials are ongoing it is likely that guidelines will need periodic revision.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →